Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal estradiol and exercise to mitigate adverse effects of androgen deprivation therapy during radiotherapy for prostate cancer
2023-504704-28-00Phase 2Authorised
- Sponsor
- Varsinais-Suomen hyvinvointialue
- Start
- Sep 2024
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of estradiol, leuprolide and tissue-plasminogen activator in prostate cancer (PCa) (4 arms), sponsored by Varsinais-Suomen hyvinvointialue. Planned start Sep 2024; status: authorised.
02
Drugs
estradiolleuprolidetissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-504704-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504704-28-00.